MK-677 Safety Profile

Safety evidence in context

MK-677 (ibutamoren, also studied as LUM-201) is an investigational small molecule, not a peptide. FDA says ibutamoren is not approved and that its safety and efficacy have not been established. The official registry lists a recruiting Phase 3 pediatric growth-hormone-deficiency trial and other studies. The earlier claim that all development stopped before Phase 3 is outdated; an active trial also does not prove safety or benefit.

The most informative longer human report is a randomized study of 65 healthy older adults. At its one-year primary assessment, fasting glucose rose on average and insulin sensitivity decreased. The most frequent reported effects were increased appetite, transient mild lower-extremity edema, and muscle pain. Fat-free mass increased, but the trial did not detect a significant strength or function gain. Its size and duration were insufficient to evaluate those endpoints, so a functional effect cannot be ruled out. The second year was exploratory, and the small sample cannot exclude uncommon harms or determine safety in other populations.

Other small trials show that metabolic results depend on the tested population and measure. In a 32-person older-adult endocrine trial, fasting glucose rose over four weeks. In a separate 24-person obese-male study, fasting glucose and insulin were unchanged, while an oral glucose-tolerance test showed impaired glucose homeostasis at two and eight weeks. Neither result supports a blanket claim that every recipient develops high fasting glucose or that a normal fasting value rules out a treatment effect.

FDA’s public warning also lists potential fatigue, water retention, muscle pain, altered glucose metabolism and insulin sensitivity, and possible increased heart-failure risk in some individuals. That warning is a safety signal, not an incidence table; the selected trials do not establish the frequency or severity of each listed event. A theoretical tumor concern from sustained GH/IGF-1 signaling should not be presented as an observed ibutamoren cancer outcome.

What remains unresolved

• Pediatric LUM-201 registries, including the completed Phase 2 study with posted results, are different populations from the older-adult and obese-male trials. They should not be merged into one safety rate.
• The 65-person older-adult trial was not powered to establish uncommon, long-latency, cardiovascular, cancer, or mortality outcomes. The current Phase 3 and extensions have not established those outcomes either.
• Registry status and an FDA orphan-drug designation do not constitute FDA marketing approval.
• WADA’s 2026 Prohibited List names ibutamoren (MK-677) under growth-hormone secretagogues.

This is a research summary, not individualized risk assessment, treatment advice, or a product-quality guide.